et al.. In vitro and in silico hormonal activity studies of di-(2-ethylhexyl)terephthalate, a di-(2-ethylhexyl)phthalate substitute used in medical devices, and its metabolites.
luminometer 96-well plates and allowed to attach for 24 h. 153 After incubation, 50 μl of a 3x dosing medium were added to the wells. The cells were 154 exposed to the dilution series of the tested chemicals (7 different concentrations of each 155 sample were tested), to the reference estrogen E2 or reference androgen DHT 156 (dihydrotestosterone), and to the solvent controls (0.1% v/v ethanol). DHT or E2 (1 nM) was 157 used as a positive control in the AR or ER agonist assay, respectively. DHT (0.25 nM) or E2 158 (0.025 nM) was used as a control in order to establish a baseline for co-exposure in order to 159 screen for AR or ER antagonism, respectively. After 24 h of exposure, the luciferase activity for the vehicle control wells was used as 100% and the results for each chemical were 170 calculated as a percentage. If the test substance showed more than 20% reduction of relative 171 cell viability, the compound was considered cytotoxic at the tested concentration. increased luminescence more than 10 per cent above the blank baseline in agonist mode, or 178 decreased luminescence by more than 20 per cent of the maximal signal in antagonist mode. 206 Enzyme linked immunosorbent assays (ELISA) were used to directly quantify testosterone 207 and 17β-estradiol from aliquots of the medium. The ELISA kits (KGE010, KGE014) were 208 purchased from Bio-Techne (R&D systems Europe, France). According to the manufacturer's 209 data, the sensitivity of the testosterone assay was 0.030 ng/mL, and the intra and inter-assay 210 coefficients of variation were 4.0% and 5.6%, respectively. The sensitivity of the 17β-211 estradiol assay was 4.84 pg/mL, and the intra-and inter-assay coefficients of variation were 212 6.0% and 7.1%, respectively. The absorbance was determined at a wavelength of 450 nm 213 using a Tecan (BioRad) microplate reader.
Release of hormones

215
Data analysis 216 Fold changes in steroids levels in the H295R steroidogenesis assay were calculated by 217 comparing the mean steroid levels of the solvent control versus the mean steroid levels in 218 medium of H295R cells exposed to the compound under investigation.
219
Statistical analysis 220
Obtained data were statistically analyzed using GraphPad Prism 6.00 (GraphPad Software binding site, as the ester is much smaller than the original ligand. There is, therefore, a wide 297 range of conformations from a single common point of interaction rather than a well-defined 298 cluster, which may indicate that, apart from this single ionic interaction, MEHT is not able to 299 find a favorable binding environment. MEHT binds well with AR with about three-fourths of 300 the 30 solutions in a single cluster irrespective of the configuration. Again, the free acid forms 301 a strong interaction with Arg 752, and it is most probable that the nearby Phe 764 would 302 reorient slightly to form a stacking. Quite unsurprisingly, these are the main interactions of 303 testosterone. The ester chain is mostly rolled up toward the aromatic ring, in a conformation 304 that is not very energetically favorable for the interaction with the receptor (Figure 3 ). both. Keeping in mind that the side chains of the residues were kept rigid, it is most probable 316 that the hydroxyl is binding to both residues in a mode very similar to that observed for the 317 natural ligand (Figure 4 ).
319
Steroids synthesis assays 320 The H295 steroidogenesis assay was performed with derived plasticizer metabolites in order 321 to detect substances which affect the production of E2 or testosterone and to understand if an 322 indirect mechanism, such as enzyme inhibition or induction, could occur. Figure 5 shows 323 statistical fold changes in hormone synthesis with the tested metabolites.
324
Estradiol synthesis 325 MEHT and MEHP were weakly active, with for MEHP a significant change between 2 and 326 40 µg/mL and a 6_fold induction at 40 µg/mL for MEHP.
327
Unfortunately MEHT was cytotoxic for the cells above 10 µg/mL. Hydroxylated derived 328 metabolites were more potent, with a concentration dependent increase in estradiol synthesis.
329
A maximum 12-fold increase was seen at 80 µg/mL. This significant effect started at a lower 330 concentration with 5-OH-MEHP (0.2 µg/mL) compared to 10 µg/mL with 5-OH-MEHT.
331
Oxo-derived monoesters were the most active metabolites, with an induction starting at 332 10 µg/mL, and reaching a 14 to 16-fold induction at the highest concentration (80 µg/mL).
333
Carboxy-derived metabolites started to be significant agonists at 40 µg/mL, but with only a 334 weak effect (around 2-fold).
335
Testosterone synthesis 336 A similar and statistically significant decrease of testosterone (2-fold) was observed with OH-337 derived metabolites. 5-OH-MEHT had an effect at a lower concentration (20 µg/mL) than 5-338 OH-MEHP (40 µg/mL). It should be noted that at 10 µg/mL, MEHT also decreased 339 testosterone synthesis. Figure 3 shows the same tendency with the oxo-derived metabolites at 340 40 and 80 µg/mL, with a change observed at a lower oxo-MEHT concentration (10 µg/mL 341 instead of 40 µg/mL with oxo-MEHP). 5-Cx-derived metabolites had no effect on 342 testosterone synthesis. 
372
It is important to note that DEHP has to be metabolized to MEHP and its derived metabolites to be greatly metabolized in vivo after oral exposure, suggesting a low probability of a direct 377 tissue exposure to the parent substances. Furthermore, long chain phthalates are converted to 378 oxidized metabolites by hepatic enzymes, then at the molecular level the adverse effects of 379 phthalates may be in fact due to effects mediated by phthalates metabolites (Kluwe, 1982) . 380 Concerning the transcriptional activity of AR, our data agree with those found by Engel et al. 381 (2017) where the authors did not observe any agonist effect on AR in the presence of DEHP 382 or its derived metabolites up to a concentration of 25 µM. However, the same authors 383 observed an AR inhibition at 50 µM, a two-fold higher concentration compared to our study. 
393
Again the sensitivity of the cell line and consequent variant sensitivity could be at the origin 394 of the differences between the data. It should be noted that the cell line we used was probably 395 not able to metabolize DEHP until ultimate active metabolites such as hydroxylated/oxidized 396 metabolites as effect in reporter gene was observed only with DEHP metabolites.
398
Using the steroidogenesis synthesis assay, which gives information on another mode of ED 399 action (not genomic), we have shown that MEHP is also active at 40 µg/mL, with an increase 400 of E2 and a decrease of testosterone. The effect was even more pronounced with its derived Cx derived metabolites had a very weak effect. In terms of estrogen synthesis, the rank order 428 potency was as follows: MEHT < corresponding OH metabolite < corresponding OXO 429 metabolite. With regard to testosterone levels, a weak but significant decrease was noted with 430 no difference between the metabolites.
431
Concerning DEHT, we lack information on this endpoint. However, it is interesting to note 432 that DEHT metabolites were more active in the steroidogenesis assay compared to DEHP can both bind to the two studied receptors in two or more different conformations, even 463 lacking any full interaction for the latter in AR. The addition of another acid group on the 464 ester chain is not optimal. 5-cx-MEHT is able to bind to the arginine of both receptors but not 465 in a well-defined conformation. There is a slightly better docking with AR than ER. 5-cx-
466
MEHP forms a large number of small size clusters in the two receptors studied, indicating an 467 unstable docking and therefore hinting at a low potential affinity, if any. Overall, the best 468 binder is clearly 5-OH-MEHT, which readily binds to ERα and AR in a mode very similar to 469 that of the natural ligands. In vitro data versus biomonitoring values 473 In neonatal intensive care units (NICU), neonates are particularly exposed to plasticizers maximum limits in the order of 5 μg/mL for these two oxidized metabolites. Our study shows 479 that at these concentrations there is an antagonistic effect on estrogen receptors. Moreover, the 480 effects of 5-OH-MEHP on the synthesis of estradiol are observed from 0.2 μg/mL, which is 481 close to the median concentration observed in these newborns. In intensive care, 482 extracorporeal membrane oxygenation (ECMO) is one of the primary medical situations that 483 exposes patients to DEHP for several days or even weeks. In particular, a study in adults has 484 shown that patients on ECMO had urinary 5-OH-MEHP concentrations of more than 5 μg/mL 485 and blood concentrations of more than 0.8 μg/mL (Huygh et al., 2015) . 486 Concerning DEHT, there is currently no biomonitoring study performed in a medical 487 environment while this plasticizer was identified in medical devices used in pediatric In this study, the biological effects of single tested metabolites appear to be weak and 500 far less potent than natural hormones. However, an observed synergic effect at low levels 501 must be taken into account and not be considered as insignificant as the human population is 502 continuously exposed to complex mixtures of chemicals in the presence of natural hormones 503 (Ghisary et al., 2009; Kortenkamp et al., 1998) . Therefore in vitro experiments are important 504 in order to monitor the effects of metabolites and can be relevant to in vivo situations, at least 505 for people with higher exposure levels, such as neonates exposed to medical devices in 506 neonatal intensive care units (Calafat et al., 2004) .
507
However, it is reassuring that the main oxidized metabolite found in the urine of 508 newborns exposed to DEHP or DEHT is the carboxylated metabolite. Our work highlights 509 that 5-cx-MEHP and 5-cx-MEHT derivatives are not active in vitro whatever the hormonal 510 activity studied. Indeed, biomonitoring studies in neonates exposed to DEHP by medical interactions, and its ester is unfavorably constrained to fit into the pockets.
531
These data, taken together with the phthalate exposure levels of neonates via medical devices, 532 demonstrate the relevance and the sensitivity of bioassays to detect hormonal activities, as 533 recommended by the level 2 OECD guidelines. They also show the importance of monitoring 534 the hormonal activities, such as antagonism or synergism, at the molecular level and their use 535 as a screening step to better protect vulnerable populations to DEHP substitutes. 536 Our study shows that investigations concerning the hazard of DEHT during exposition of 537 neonates to medical devices must be monitored before attesting to its safety. Several elements 538 play in favor of this plasticizer as an alternative to DEHP: its weak diffusion towards the 539 liquids in contact with the medical devices limiting the exposure of the patients, its less 540 toxicity compared to the DEHP (cytotoxicity, carcinotoxicity, reprotoxicity). However, the 541 results of our study lead to caution with respect to the potential endocrine disrupting effect of 542 the hydroxylated metabolite (5-OH-MEHT). It should be ensured that the urinary levels of 543 this metabolite are lower than the concentrations that have shown co-stimulation of estrogen 544 receptors, and an increase in estrogen synthesis. 
